Alyftrek 4-20-50 MG tablet 21S
Ended Awarded
- Contract number
- SPE2DB26FX1KN
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,993
Award facts
- Contract value 100% obligated
- $20,993.31 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $20,993.31 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for ALYFTREK 4-20-50 mg tablets (21-count units). The award was issued on October 29, 2025, with an ultimate completion date of October 30, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. holds a prime contract under PPV-G GEN V designated as SPE2DR, with a ceiling value of $499,999,999 and completion through December 31, 2036, featuring a 30-month base period with three 30-month option periods. The contractor's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. As a critical supplier within the federal pharmaceutical supply chain since its SAM registration in 2001, DMS Pharmaceutical Group has demonstrated consistent performance across multiple delivery orders issued by the DLA's Medical Supply Chain division, supporting the department's diverse and specialized pharmaceutical requirements across military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FX1KN?
SPE2DB26FX1KN was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FX1KN worth?
The government has obligated $20,993 on SPE2DB26FX1KN.
Is contract SPE2DB26FX1KN an order under another contract?
Yes. SPE2DB26FX1KN is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KN competed?
The extent of competition for SPE2DB26FX1KN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award